Skip to main content

Advertisement

Table 4 Performance of Models for the composite endpoint of all-cause mortality and readmission due to heart failure

From: Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction

Marker C-statistic (p value) Nagelkerke’s R2 cNRI Reclassification
Composite endpoint
 Clinical model (CM) 0.815 0.645   
  CM + Stanniocalcin-2 0.821 (p = 0.100) 0.660 0.125 (− 0.053–0.363) 3.8% (0.9–6.9%)
  CM + IGFBP-4 0.823 (p = 0.113) 0.671 0.270 (0.064–0.431) 5.0% (2.2–8.9%)
  CM + Stanniocalcin-2 + IGFBP-4 0.826 (p = 0.036) 0.677 0.176 (0.001–0.420) 6.2% (3.1–9.6%)
All-cause mortality
 Clinical model (CM) 0.807 0.636   
  CM + Stanniocalcin-2 0.808 (p = 0.555) 0.646 0.129 (− 0.129–0.330) 2.4% (0.3–4.8%)
  CM + IGFBP-4 0.814 (p = 0.241) 0.662 0.248 (0.001–0.412) 3.7% (1.2–6.6%)
  CM + Stanniocalcin-2 + IGFBP-4 0.814 (p = 0.204) 0.664 0.185 (− 0.041–0.433) 4.1% (1.6–7.0%)
Readmission due to heart failure
 Clinical model (CM) 0.861 0.802   
  CM + Stanniocalcin-2 0.872 (p = 0.211) 0.825 0.256 (− 0.129–0.653) 1.31% (0.2–3.0%)
  CM + IGFBP-4 0.861 (p = 0.103) 0.806 0.114 (− 0.285–0.446) 0.4% (0.0–1.9%)
  CM + Stanniocalcin-2 + IGFBP-4 0.869 (p = 0.413) 0.823 0.239 (− 0.148–0.611) 1.6% (0.3–3.1%)
  1. Clinical model includes: age, sex, history of arterial hypertension, diabetes mellitus, heart failure, myocardial infarction, glomerular filtration rate and left ventricular ejection fraction
  2. IGFBP-4 insulin-like growth factor binding protein-4